What is NKTX's market cap?

Nkarta, Inc. (NKTX) is a listed stock with a live quote. The latest market cap on this page is $112M.

Where is Nkarta, Inc. headquartered?

Nkarta, Inc. is headquartered in South San Francisco, CA.

How do I get NKTX news from the API?

Call GET /v1/news?tickers=NKTX. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.

How far back does NKTX news go?

Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for NKTX, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.

Is the NKTX price on this page from the API?

The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.

Can I use the Pro plan commercially?

No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email sales@marketnewsapi.com.

NKTX · NASDAQ

Nkarta, Inc.

$1.57 -0.16 (-9.25%)

Company overview

Nkarta, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes cell therapies for cancer treatment. The company's approach to cellular immunotherapy involves chimeric antigen receptors on the surface of natural killer (NK) cells that enable the cells to recognize specific proteins or antigens present on tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher-risk myelodysplastic syndromes, and NKX019, a preclinical product designed to treat various B cell malignancies by targeting the CD19 antigen found on these cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
Market cap: $112M
Employees: 157
Headquarters: South San Francisco, CA
Website: nkartatx.com
CEO: Paul J. Hastings
Listed: July 10, 2020
P/E: -1.17
Dividend yield: 0.00%

Company financials

Revenue: $0.00
Gross profit: -$2.3M
Operating income: -$116M
EBITDA: -$102M
Net income: -$99.9M
EPS: -$1.34
Total assets: $372M
Total debt: $75M
Earnings yield: -85.35%

Price chart

NKTX 1D NASDAQ O1.58H1.75L1.56C1.73+0.20 (+13.07%)Vol1.85M

News

Ticker	Type	Headline	Source	Published
NKTXNkarta, Inc.	Press release	Nkarta Reports Third Quarter 2026 Financial Results and Provides Business Update	GlobeNewswire	Nov 5, 4:34:42 PM ET
NKTXNkarta, Inc.	Stock news	Nkarta Targets ACR 2026 Data Reveal as Outpatient CAR NK Trials Advance	MarketBeat	Sep 27, 3:02:18 PM ET
NKTXNkarta, Inc.	Stock news	Nkarta (NASDAQ:NKTX) Stock Falls 3.5% – Here’s Why	Defense World	Sep 27, 6:01:47 AM ET
NKTXNkarta, Inc.	Press release	Nkarta to Participate in September Investor Conferences	GlobeNewswire	Sep 10, 7:00:00 AM ET
NKTXNkarta, Inc.	Press release	Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026	GlobeNewswire	Sep 8, 7:00:00 AM ET
NKTXNkarta, Inc.	Stock news	6,300,212 Shares in Nkarta, Inc. $NKTX Acquired by BlackRock Inc.	Defense World	Sep 4, 3:26:55 AM ET
NKTXNkarta, Inc.	Stock news	The $13 Million Company Teaching the Immune System to Hunt Cancer	PRNewsWire	May 29, 9:00:00 AM ET
NKTXNkarta, Inc.	Press release	Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights	GlobeNewswire	May 12, 4:01:00 PM ET
NKTXNkarta, Inc.	Stock news	NKTX Stock Up on Upbeat Regulatory Update on Lead Autoimmune Program	Zacks Investment Research	Apr 17, 11:30:11 AM ET
NKTXNkarta, Inc.	Press release	Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers	GlobeNewswire	Apr 15, 4:01:00 PM ET
NKTXNkarta, Inc.	Press release	Nkarta to Participate in Needham Virtual Healthcare Conference	GlobeNewswire	Apr 9, 7:00:00 AM ET
NKTXNkarta, Inc.	Stock news	Nkarta, Inc. (NASDAQ:NKTX) Given Average Recommendation of “Hold” by Analysts	Defense World	Apr 6, 2:20:54 AM ET
NKTXNkarta, Inc.	Press release	Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights	GlobeNewswire	Mar 25, 4:01:00 PM ET
NKTXNkarta, Inc.	Stock news	Bolt Biotherapeutics (NASDAQ:BOLT) versus Nkarta (NASDAQ:NKTX) Head to Head Review	Defense World	Mar 3, 1:14:49 AM ET
NKTXNkarta, Inc.	Press release	Nkarta to Participate in March Investor Conferences	GlobeNewswire	Feb 27, 8:00:00 AM ET
NKTXNkarta, Inc.	Stock news	Nkarta, Inc. $NKTX Shares Sold by AWM Investment Company Inc.	Defense World	Dec 13, 2025, 3:50:49 AM ET
NKTXNkarta, Inc.	Press release	Nkarta to Participate in Evercore Healthcare Conference	GlobeNewswire	Dec 2, 2025, 7:09:00 AM ET
NKTXNkarta, Inc.	Stock news	Nkarta: Pushing Deeper And Deeper Into A Discount Vs. Their Holdings, For No Real Reason	Seeking Alpha	Nov 22, 2025, 8:28:11 AM ET
NKTXNkarta, Inc.	Press release	Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights	GlobeNewswire	Nov 10, 2025, 4:01:00 PM ET

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.